UNSPSC 51363102: Amiperone

This classification denotes an antipsychotic agent with the molecular formula C24H28ClFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FTX5V7543O, chemically known as 4-piperidinecarboxamide, 4-(4-chlorophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-n,n-dimethyl- (9ci) but generally known as amiperone, which bears US NIH Compound Identifier 71101. European Medicines Agency schedules Amiperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05452MIG.

UNSPSC 51363102 Amiperone is a Commodity code that in practice encompasses pharmaceutical procurement across state and local health and human services agencies, though recent solicitation activity under this specific code shows minimal relevant volume. State and local governments issue opportunities under this code through county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. The actual work being solicited reflects broader pharmaceutical supply chains — generic multi-source drugs, over-the-counter products, emergency medications like naloxone, and direct-to-manufacturer prescription programs — rather than amiperone specifically. Issuing bodies typically require vendors to meet FDA compliance, cGMP and Drug Supply Chain Security Act (DSCSA) certification, maintain relationships with authorized wholesale distributors, carry comprehensive insurance including commercial general liability and professional liability coverage, and comply with E-Verify and drug-free workplace requirements. Contracts generally run two years with optional renewals and are awarded on fixed-fee or negotiated net-pricing bases with performance penalties for late reporting or missed milestones.

Recent activity centers on Florida and Minnesota through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products in January 2026 with proposals due March 26, 2026, requiring vendors to work through authorized wholesalers including AmerisourceBergen Drug Corporation and Cardinal Health with awards effective July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows sparse recent activity specifically tagged to amiperone; procurement volume under this Commodity code in state and local markets appears limited relative to broader pharmaceutical family categories.